HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

PHASE3CompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

July 31, 2024

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

Hepatic arterial infusion chemotherapy

PROCEDURE

Transarterial chemoembolization

DRUG

TACE regimen

infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)

DRUG

HAIC Regimen

Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin

DRUG

Oral Sorafenib

Oral Sorafenib, 400mg, Bid

Trial Locations (7)

421001

The First Affiliated Hospital of University Of South China, Hengyang

510060

Cancer Center Sun Yat-sen University, Guangzhou

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

510620

Guangzhou Twelfth People 's Hospital, Guangzhou

523059

Dongguan People's Hospital, Dongguan

529300

Kaiping Central Hospital, Kaiping

710061

The First Affiliated Hospital Of Xi'an Jiaotong University, Xi’an

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02856126 - HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC | Biotech Hunter | Biotech Hunter